IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL5.67▼ 0.02% USD/MXN18.58▲ 0.40% USD/CLP994.16▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN3.41▲ 0.11% USD/ARS1,544▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 — 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES911.74▼ 0.13% USD/PAB1.00— 0.00% USD/BZD2.00— 0.00% USD/JMD157.69— 0.00% USD/TTD6.75— 0.00% EUR/BRL6.25▼ 0.04% BRENT 96.33 ▲ 0.51% WTI 89.23 ▲ 0.76% IRON ORE 161.91 — — COPPER 6.03 ▼ 0.76% GOLD 3,862 ▼ 0.63% SILVER 47.33 ▼ 3.47% SOY 1,227 ▼ 1.33% CORN 444.50 ▼ 0.22% WHEAT 589.25 ▼ 0.67% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 78.68 ▲ 0.01% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00% IBOV 172,457.76 ▲ 0.66% IPC MEX 71,204.98 ▼ 0.84% MERVAL 2,848,945 — — USD/BRL 5.67 ▼ 0.02% USD/MXN 18.59 ▲ 0.45% USD/CLP 994.16 ▼ 0.13% USD/COP 3,303 — 0.00% USD/PEN 3.41 ▲ 0.15% USD/ARS 1,544 ▼ 0.02% USD/UYU 40.59 — 0.00% USD/PYG 6,196 — 0.00% USD/BOB 11.59 — 0.00% USD/DOP 60.59 — 0.00% USD/CRC 442.74 — 0.00% USD/GTQ 7.64 — 0.00% USD/HNL 26.91 — 0.00% USD/NIO 36.62 — 0.00% USD/VES 911.74 ▼ 0.13% USD/PAB 1.00 — 0.00% USD/BZD 2.00 — 0.00% USD/JMD 157.69 ▲ 2.75% USD/TTD 6.75 ▲ 2.58% EUR/BRL 6.25 ▼ 0.04% BRENT 96.33 ▲ 0.51% WTI 89.23 ▲ 0.76% IRON ORE 161.91 — — COPPER 6.03 ▼ 0.76% GOLD 3,862 ▼ 0.63% SILVER 47.33 ▼ 3.47% SOY 1,227 ▼ 1.33% CORN 444.50 ▼ 0.22% WHEAT 589.25 ▼ 0.67% COFFEE 279.25 ▼ 0.34% SUGAR 18.40 ▲ 0.99% ORANGE JUICE 136.85 ▼ 2.91% COTTON 78.68 ▲ 0.01% COCOA 5,123 ▲ 1.13% BEEF 224.80 ▲ 2.70% CATTLE 335.35 ▼ 0.10% LITHIUM 58.76 ▼ 1.13% PETR4 45.30 — 0.00% VALE3 63.50 — 0.00% ITUB4 42.27 — 0.00% BBDC4 14.52 — 0.00% ABEV3 15.79 — 0.00% BBAS3 15.10 — 0.00% B3SA3 14.89 ▲ 0.88% WEGE3 51.31 ▼ 0.66% PRIO3 63.30 — 0.00% SUZB3 54.77 — 0.00% RENT3 30.07 — 0.00% AZZA3 15.91 — 0.00% CSAN3 3.10 ▲ 8.77% RAIZ4 20.00 — 0.00% PCAR3 2.56 ▲ 7.11% GMAT3 4.25 ▲ 10.68% PSSA3 46.41 ▲ 1.02% CVCB3 0.83 ▼ 1.19% POSI3 3.15 ▼ 6.53% SLCE3 18.28 ▼ 0.44% NATU3 5.13 ▼ 3.75% BRKM5 3.02 — 0.00% RANI3 8.18 — 0.00% CSNA3 3.72 — 0.00%
since 2009
Monday, November 16, 2026

Covid-19 Brazil

Study finds that AstraZeneca vaccine’s 3rd dose produces strong immune response

By · · 2 min read

RIO DE JANEIRO, BRAZIL – A third dose of AstraZeneca’s Covid-19 vaccine from Oxford University produces a strong immune response, researchers said Monday, adding that there is no evidence yet that such a booster dose is required, particularly given vaccine shortages in some countries.

1
AstraZeneca vaccine’s 3rd dose produces strong immune response.
RT
Ask Rio Times
This story and the bigger picture.
Open the full Ask Rio Times →

The Oxford University study showed that a third dose of the vaccine boosts antibody and T-cell immune responses, while the second dose administration may be delayed until up to 45 weeks after the first and still lead to an enhanced immune response.

The UK government says it is considering plans for a booster dose campaign in the Northern Hemisphere autumn, with three-fifths of adults having been administered both Covid-19 vaccine doses.

Andrew Pollard, director of the Oxford Vaccine Group, said that evidence that the vaccine protects against existing variants for a sustained period means that a booster dose may not be required.

“We need to be in a position where we can administer the booster dose should it prove necessary … (but) we have no indication that it will be,” he told reporters.

The LatAm Brief

One email, every weekday morning. What moved in Latin American markets, politics and expat life.

Yesterday’s subject line: “Exxon gets Guyana approval for a gas project”

“At the moment, with a high protection rate in the UK population and no evidence that this has been lost, administering third doses in the UK while other countries have zero doses is not acceptable.”

Earlier studies have shown that the vaccine, developed by Oxford University and licensed by AstraZeneca, has a higher efficacy when the interval between doses is extended to 12 weeks rather than 4 weeks.

The research announced on Monday was released in a pre-print, with no peer review by other scientists, and analyzed 30 participants who were administered a delayed second dose and 90 who were administered a third dose. All participants were under the age of 55.

The study helps ease concerns that viral vector-based Covid-19 vaccines, such as AstraZeneca and Johnson & Johnson’s may lose their potency if annual booster doses are required, given the risk that the body will produce an immune response against the vectors carrying the vaccine’s genetic information.

“There have been some concerns that we couldn’t use this vaccine on a booster dose regimen, and that’s certainly not what the data are suggesting,” study author Tereza Lambe of Oxford’s Jenner Institute said.

This article was produced by The Rio Times’ automated AI newsroom. Editorial responsibility: Matthias Camenzind, Publisher and Editor-in-Chief. The Rio Times also runs Ask Rio Times, which answers from 100,000+ of our own articles, the daily Latin America Power Map, and prediction-market odds on elections and markets.. How we use AI · Report an error

The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →

Brazil runoff date: Sunday, October 25, poll closing times and when results start · Brazil runoff polls: Flávio 51%, Lula 49% · Kalshi and Polymarket odds

Rotate for Best Experience

This report is optimized for landscape viewing. Rotate your phone for the full experience.